Drugs / Myeloma vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02728102 | Jul 2016 → Jun 2020 | plasma cell myeloma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Myeloma vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02728102 ↗ |
| Modality | Vaccine | “Patients will receive the DC/MM fusion vaccine on day 1 of cycles 2, 3, and 4 of lenalidomide maintenance.” NCT02728102 ↗ |
| Route | Subcutaneous | “Vaccine will be administered by subcutaneous injection in the upper thigh.” NCT02728102 ↗ |